SCHEMBL21145375

SCHEMBL21145375

O=C(O)N1CCCC(F)(c2nnc(-c3ccnc(Br)c3)o2)C1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 10/20 0.53
NPC1 O15118 5/20 0.35
RAB9A P51151 5/20 0.35
ALDH1A1 P00352 4/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
MEN1 O00255 2/20 0.35
HPGD P15428 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPK1 P28482 1/20 0.35
PROKR1 Q8TCW9 1/20 0.35
PDK2 Q15119 3/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21145374 1.00 USP30 (0.53) USP30NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21145373 0.86 USP30 (0.72) USP30NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21145371 0.86 USP30 (0.72) USP30NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21145389 0.85 USP30 (0.51) USP30NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21145388 0.85 USP30 (0.51) USP30NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21145394 0.82 USP30 (0.75) USP30NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21145395 0.79 USP30 (0.74) USP30
SCHEMBL20028870 0.72 USP30 (0.46) USP30
SCHEMBL29679555 0.72 USP30 (0.46) USP30
SCHEMBL20028871 0.71 USP30 (0.67) USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109790148-B Cyano-substituted heterocycles having USP30 inhibitor activity 特殊治疗有限公司 2022-06-07 CN disclosed
EP-3519397-B1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2021-05-19 EP disclosed
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-02-23 US disclosed
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 USP30, USP28, USP1 USP30 1/4885NPC1 3401/4885RAB9A 3028/4885
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 USP30, USP28, USP1 USP30 1/4885NPC1 3401/4885RAB9A 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.